LDLR抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of Hela cells using LDLR mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancertissues using LDLR mouse mAb with DAB staining.    

  
  

Low-density lipoprotein receptor (LDLR) antibodies are tools used to study the LDLR, a cell-surface protein critical for regulating cholesterol homeostasis. LDLR mediates the uptake of LDL cholesterol particles via receptor-mediated endocytosis, a process essential for maintaining plasma cholesterol levels. Dysfunctional LDLR, often due to genetic mutations, is linked to familial hypercholesterolemia (FH), a condition characterized by elevated LDL cholesterol and increased cardiovascular risk.

LDLR antibodies, including monoclonal and polyclonal types, are widely employed in research to detect LDLR expression, track its intracellular trafficking, or modulate its activity. For example, some antibodies act as antagonists to block LDL binding, mimicking therapeutic strategies like PCSK9 inhibitors, which enhance LDLR recycling and lower cholesterol. Conversely, agonist antibodies may stabilize LDLR to boost LDL clearance. These applications make LDLR antibodies valuable in studying atherosclerosis, metabolic disorders, and lipid metabolism pathways.

Additionally, LDLR antibodies have diagnostic potential, aiding in identifying FH patients with receptor defects. Emerging therapeutic approaches also explore antibody-based targeting of LDLR to treat hypercholesterolemia or cancers where LDLR is overexpressed. However, challenges remain in ensuring specificity and minimizing off-target effects. Overall, LDLR antibodies serve as pivotal reagents in both basic research and translational studies of cholesterol-related diseases.